Aquestive Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Aquestive Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-06-30 was 7.50K shares.
- Aquestive Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2024-03-31 was 231.40K shares.
- Aquestive Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2023-09-30 was 625.00 shares.
- Aquestive Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 0.00 shares, a 100.00% decline from fiscal 2021.
- Aquestive Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2021 was 61.00K shares.
- Aquestive Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2020 was 0.00 shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2025-06-30 | 7.50K shares 10-Q · filed 2025-11-05 | |
| 2024-03-31 | 231.40K shares 10-Q · filed 2024-11-04 | |
| 2023-09-30 | 625.00 shares 10-Q · filed 2024-11-04 | |
| 2022-12-31 | 0.00 shares 10-K · filed 2023-03-31 | |
| 2021-12-31 | 61.00K shares 10-K · filed 2023-03-31 | |
| 2020-12-31 | 0.00 shares 10-K · filed 2022-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |